SpectraScience Wins Approval for Optical Biopsy System
MINNEAPOLIS & ST. PAUL, Minn., Dec. 5 -- SpectraScience Inc. said the US Food and Drug Administration (FDA) has notified the company that its second-generation WavSTAT II Optical Biopsy System has been approved for clearance to market. SpectraScience submitted a supplement to the original premarket approval application (PMA) of the WavSTAT I Optical Biopsy System and was granted an expedited "real-time review" by the FDA. The clinical and medical indications for WavSTAT II are the same that were granted for WavSTAT I for use as an aid to physicians for endoscopic colorectal cancer screening.
Chet Sievert, SpectraScience chairman and CEO, said, "We are extremely delighted that the FDA was so prompt in reviewing and approving our next-generation Optical Biopsy System, WavSTAT II. WavSTAT II incorporates features and enhancements recommended by our clinical partners over the course of the ongoing cost-effectiveness and clinical outcome studies performed with the first-generation system. The company believes WavSTAT II simply is a smaller, more user-friendly system."
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024